1. Ultraman said that he would not hesitate to burn $50 billion to develop general-purpose AI. 2. OpenAI, the parent company of ChatGPT, registers lobbying firm in California. 3. Xiaomo Investment Consultant GPT was officially unveiled: the expectation is full, and the reality is skinny. 4. What do you think of AI?Warren Buffett: I don't know anything about artificial intelligence, it has a lot of potential. 5. National University Hospital Singapore's new Digestive Health Centre: Uses AI to quantify scores and detect early signs of cancer. 6. TSL shares a video of the second-generation Optimus robot in action: the battery can be precisely inserted into the tray. 7. It is reported that the "AI godmother" Li Feifei is building a startup to develop an AI system that can understand the relationship between 3D shorts. 8. Behind the popularity of the AI track, engineers from large factories complained: the company sacrificed accuracy for the sake of speed. 9. Face Wall Intelligence released Eurux-8x22B Open Source large model: code performance surpasses Llama3-70B.

On May 4, on May 3, Ukrainian President Volodymyr Zelensky signed a new mobilization bill to allow asymptomatic people living with HIV, hepatitis, cancer patients whose condition is deteriorating slowly, tuberculosis patients and mental patients to enlist in the army. In addition, pregnant women without complications are being mobilized.

On April 29th, Golden Ten Data reported that Kexing Pharmaceutical has reached an international commercialization licensing agreement with Qinfeng Pharmaceutical's subsidiary, Kerui Pharmaceuticals, for Olaparib tablets. Kexing Pharmaceutical has obtained the commercialization rights of Olaparib tablets in the first batch of 10 countries overseas through Qinfeng Pharmaceutical. Olaparib tablets are PARP (Poly ADP-ribose Polymerase) inhibitors. The original drug was first approved by the U.S. FDA in 2014 for the treatment of advanced ovarian cancer with BRCA mutations. Subsequently, its indications have been expanded to include various malignant tumors such as ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It is recommended as a first-line treatment for breast cancer and a first-line maintenance treatment for ovarian cancer in the NCCN Clinical Practice Guidelines.

PANews reported on February 19 that the latest Startup Request (RFS) of Y Combinator (YC), a well-known American startup incubator, highlighted the innovative areas they want to see more Long people engage in. These areas include applying machine learning to robotics, using machine learning to simulate the physical world, new defense technologies, bringing manufacturing back to the United States, new Short Companies, climate tech, commercial Open Source companies, Short Computing, new enterprise resource planning software, developer tools inspired by existing in-house tools, explainable artificial intelligence, large language models (LLMs) for traditional enterprise back-office manual processes, building enterprise software with AI, Stable Coin Finance, ways to end cancer, The foundational model of biological systems, the managed services organization model of healthcare, the elimination of middlemen in healthcare, the better enterprise software "glue", and the small fine-tuned model as an alternative to the giant general-purpose model. Regarding the Stable Coin financial component, YC said that there is a lot of debate about the usefulness of Blockchain technology Long, but it is clear that Stable Coin will be an important part of the future of the currency. $136 billion worth of Stable Coins have been issued in the market, but the opportunity seems to be far from being fully tapped. So far, only about seven million people have traded Stable Coins, while more than half a billion people live in countries with annual Inflation rates above 30%. U.S. banks hold a total of $17 trillion in customer deposits, which are potential conversion targets. However, there are only a handful of major Stable Coin issuers, and even fewer major Liquidity Providers. Y Combinator wants to fund the talented teams that build B2B and consumer products, tools, and platforms on top of the Stable Coin, as well as more Long Stable Coin the protocol itself.

According to a report by Blue Whale Finance on December 27, the State Food and Drug Administration announced that the lung surgery planning products of Inference Medical have passed the approval of Class III medical devices. This product is used for lung surgery planning, and is the first artificial intelligence application for cancer surgery treatment approved by the State Food and Drug Administration for Class III certificate in China, and the first and only lung surgery planning product approved by the State Food and Drug Administration for Class III certificate, which can provide a reference for thoracic surgeons to formulate lung surgery plans.

Researchers at the University of Texas Southwestern Medical Center in the United States have developed a new artificial intelligence (AI) model that analyzes the spatial arrangement of cells in tissue samples, as reported by the Financial Associated Press on December 13. The innovative approach, published Dec. 11 in Nature Communications, accurately predicts outcomes for cancer patients, marking a significant advance in the use of AI for cancer prognosis and personalized treatment strategies.

1.China Telecom establishes a new AI technology company with a registered capital of 3 billion yuan 2.For $51 million, OpenAI will buy AI chips from startups invested by CEO Altman 3.AstraZeneca signs a $247 million agreement with AI biopharmaceutical company Absci to collaborate on the development of anti-cancer drugs 4.Nature: AI creates 41 new materials on its own in just 17 days, surpassing humans in speed and accuracy 5.Research: ChatGPT Promise to provide a "tip" when asking a question and get a more detailed reply 6.Meta Chief Scientist Yang Likun refuted Huang Jenxun: Superintelligence won't come soon 7.Emdoor Information: A PC platform built for generative AI is being developed

AstraZeneca, a pharmaceutical company in the United Kingdom and Sweden, has signed a deal worth up to $247 million with Absci, a U.S. artificial intelligence (AI) biologics company, to design an antibody to fight cancer, as reported by Webmaster's House on December 4. Absci's collaboration with AstraZeneca aims to develop a zero-cycle generative AI model that aims to create new and improved antibody therapeutics. The company did not say what type of cancer they plan to target. Sean McClain, CEO of Absci, said: "We are proud to be working closely with AstraZeneca to leverage our AI to bring new treatment options to oncology patients. ”

PANews reported on November 9 that according to Cointelegraph, Yuga Labs confirmed that at least 15 participants at the Yuga Labs ApeFest event held in Hong Kong last week had vision loss, eye pain and skin problems, and ultraviolet (UV) lamps may be the cause of the problem, but BAYC did not disclose specific details of the types of UVA lamps used on ApeFest. Previously, on November 5, after attending the previous day's ApeFest, attendees began reporting eye and skin-related issues. Yuga Labs encouraged symptomatic individuals to seek medical help and inform them about their exposure to UVA lamps, and also asked affected individuals to message them on X saying they would support support the recovery of those affected. According to the World Health Organization, UVA is a range of ultraviolet wavelengths that accounts for about 95% of the ultraviolet radiation that reaches the Earth's surface. According to the National Eye Institute, UV exposure may increase the risk of eye problems. The UVA band is part of the ultraviolet wavelength division, also known as long-wave black spot effect ultraviolet light. It has a strong penetrating power, and UVA can reach the dermis layer of the skin, destroying elastic fibers and collagen fibers, and tanning the skin. Ultraviolet radiation (including UVA, UVB and UVC) was included in the list of carcinogens published by the World Health Organization's International Agency for Research on Cancer.

Odaily Planet Daily reported that VitaDAO, a DeSci (decentralized science) project invested by pharmaceutical giant Pfizer, recently spun off a biotechnology company, Matrix Biosciences. Matrix Biosciences, a biotech company led by Vera Gorbunova, an anti-aging researcher at the University of Rochester, has an initial funding of $300,000 for the project, with more funding to be available in early 2024. The company aims to conduct research on the longevity and cancer-fighting properties of naked mole rats, and to study whether compounds found in naked mole rats could extend human lifespan. (blockworks)

VitaDAO Founds Biotech Firm to Advance Longevity Research, Develop Treatments for Cancer and Age-related Diseases VitaDAO, a decentralized autonomous organization (DAO), has launched Matrix Biosciences, a biotech company focused on advancing longevity research. Matrix Biosciences, majority-owned by VitaDAO, will operate as a centralized entity and work on developing treatments for cancer and age-related diseases using research on the naked mole-rat. The company aims to demonstrate the compatibility of blockchain technology with the biotech industry and is actively collaborating with regulators to ensure compliance.

PANews reported on October 9 that according to Decrypt, VitaDAO, a decentralized autonomous organization that aims to fund longevity research projects, has cooperated with famous biologist Vera Gorbunova to establish Matrix Biosciences, a biotechnology company that studies longevity. The company’s majority shareholder is VitaDAO, but due to the strict legal environment in the medical and healthcare fields, the company itself will still operate as a traditional company. VitaDAO will initially provide $300,000 in funding to Matrix Biosciences. The joint venture will then receive additional capital through its IP-NFT segmentation model. VitaDAO core member Eleanor Davies said Matrix Biosciences will study the anti-cancer, anti-pain and life-extending properties of a special substance rich in high molecular weight hyaluronic acid (HMW-HA) secreted by naked mole rats. It was reported in January this year that VitaDAO, a longevity research organization, completed US$4.1 million in financing, with Pfizer’s venture capital firm participating in the investment. Related reading: Can VitaDAO, which received investment from Pfizer, start a new narrative of decentralized science?

Golden Finance reports that VitaDAO, a community organization that funds and promotes early longevity research, announced that it has partnered with world-renowned biologist Vera Gorbunova to establish Matrix Biosciences. Gorbunova, a professor at the University of Rochester, is credited with discovering the anti-cancer properties of naked mole rats. Todd White, a core member of VitaDAO, said the idea behind the new company is to “bring the research within the DAO back into the real world” rather than keeping it on-chain. Matrix Biosciences will operate centrally like a traditional company.

According to reports from the financial industry on October 4, JPMorgan Chase CEO Jamie Dimon believes that the benefits of artificial intelligence will far outweigh the disadvantages. In a recent interview, Dimon acknowledged that AI will displace some jobs, but said that pales in comparison to the benefits it will bring to the world. "Technology is always going to replace jobs," Dimon said. "Your kids will live to be 100 years old and not get cancer because of technology. In fact, they may only have to work three and a half days a week." Dimon said artificial intelligence The biggest disadvantage of intelligence is that it can be exploited by bad people who want to do bad things. However, the benefits are limitless.

According to a report by Science and Technology Innovation Board on September 19, the U.S. Department of Defense and Google have cooperated to develop a new microscope with AI functions that can help doctors detect the presence of cancer cells in patients earlier. American doctor Nadeem Zafar said in an interview that the new product is called Virtual Reality Microscope (ARM). The technology is still in its early stages and has not yet been actively used in diagnosis and treatment, but the initial research and development is progressing well. Zafar said that 13 ARMs have been produced so far and are in the testing phase at the Miter Institute in Washington, the capital. Officials say it could be a useful tool for pathologists. According to estimates, each ARM may cost US$90,000 to US$100,000.

According to Reuters, on September 14, Generate:Biomedicines, a drug developer that uses artificial intelligence (AI) to find new treatments, announced that it had raised 273 million from investors including Nvidia Ventures and Amgen. USD funds. The company said it will use the Series C financing to support its drug research and development in different disease areas such as cancer, infectious diseases and immune diseases. It is reported that the artificial intelligence-driven drug developer has raised approximately US$700 million in equity financing since 2020.

1. NVIDIA releases TensorRT-LLM, which can improve H100 inference performance by up to 8 times 2. Microsoft collaborates with Paige to build the world's largest image-based AI model to identify and detect cancer 3. G20 member states approve the regulation of crypto assets to mitigate related risks The regulatory roadmap will be discussed in October. 4. The metaverse platform Roblox plans to launch on Sony PlayStation platform in October this year. 5. Wang Xiaohang, Vice President of Ant Group: All key links in the financial field are worth transforming with large model technology.

According to a report from the Financial Associated Press on September 10, Microsoft announced on Thursday that it will cooperate with digital pathology provider Paige to build the world's largest image-based artificial intelligence model for identifying cancer. The AI model is being trained on an unprecedented amount of data, including billions of images, according to a press release. It can identify common and rare cancers that are difficult to diagnose.

According to a report by Xinhua News Agency on September 5, the Technion-Israel Institute of Technology recently issued a communiqué stating that its researchers have developed an innovative method that combines biology, chemistry and artificial intelligence tools to treat cancer. Related papers were published in the international journal "Journal of Controlled Release". According to the communique, this therapy is based on the concept of "meta-synergy", which means that with the help of efficient artificial intelligence tools, different drugs work together to form nanoparticles through a self-assembly chemical process, achieving a more significant therapeutic effect than a single drug. The nanomedicine produced by this tool can effectively implement targeted therapy on cancer cells, and is more successful in fighting cancer, with less toxicity and fewer side effects.

According to DoNews, on August 16, the medical AI team of Ali Dharma Institute, together with Sun Yat-sen University Cancer Center, Sichuan Cancer Hospital, Zhejiang University First Affiliated Hospital, Shengjing Hospital, Guangdong Provincial People's Hospital and other units, proposed a unified Multi-cancer image analysis universal model (cancerUniT), based on Mask Transformer semantic segmentation, solves the problem of unified detection, segmentation and diagnosis of various tumor images, and is applicable to eight mainstream high-incidence and high-lethal cancers (lung, colorectal, Liver, stomach, breast, esophagus, pancreas, kidney) and tumor subtypes in related organs. It is understood that the paper results of this model have been included in ICCV 2023, the top conference of computer vision, and have been applied and tested in Shanghai First People's Hospital and other cooperative hospitals.

According to a report from the Webmaster's House on August 14, Microsoft Research believes that GPT-4 is sufficient for medical tasks, can speed up medical processes and improve efficiency. Large language models (LLMs) such as GPT-4 have huge potential in the medical field, according to the Microsoft Research team. These models can help speed up medical processes, such as improving the efficiency of cancer drug development by processing large-scale unstructured patient data. Microsoft has also introduced language models such as BioGPT specifically for medical tasks, but has now made it clear that it will mainly rely on GPT-4 in the future. In addition, Microsoft is developing the "LLaVA-Med" model to more closely integrate medical data and research to accelerate medical care and research.

According to the "Kechuangban Daily" report on July 20, recently, Gaowei Medicine completed an angel round of financing of tens of millions of RMB. This round of financing was jointly invested by many well-known investment institutions such as Betta Biomedical Industry Fund and West Lake Innovation Investment. . The funds from this round of financing will be mainly used to support Gaowei Pharmaceuticals in establishing a high-dimensional biology-driven innovative drug discovery platform to meet the needs of R&D investment and application promotion for providing innovative drug solutions for major diseases such as cancer and neurodegenerative diseases. High-dimensional Medicine is a high-dimensional biology AI drug design platform developer, committed to building a world-leading high-dimensional biology + AI drug design platform, using future computing to empower traditional drug research and development, for major neurodegenerative diseases, tumors, etc. Disease provides innovative solutions for first-in-class and best-in-class drugs.

According to a report by Jinshi on July 4, British Prime Minister Sunak emphasized in his speech the great potential of artificial intelligence (AI), including the possibility of curing incurable diseases such as cancer and dementia, as well as the potential of AI in the fields of economy, medical care and education. widely used. AI is seen as a general-purpose technology that increases productivity, but requires commensurate investment to make it happen. In this regard, he cites a recent report by PwC, which predicts that AI will bring a 10% benefit to the UK's gross domestic product (GDP) in the next decade. Sunak said there is huge potential for AI applications in the public service, especially in healthcare and education. In healthcare, speeding up diagnosis and improving diagnostic accuracy for diseases such as skin cancer. In education, reduce the workload of teachers and provide personalized teaching. At the same time, he mentioned that one of the risks of AI is the risk of abuse, whether it is an open source model or otherwise, they may be used as a tool to generate false information, or the risk of being exposed to other harmful content or comments. Another risk of AI is the risk of tool usage, that is, the underlying model can activate various capabilities in the real world. The last risk is what people call "overcapacity," which is more about potential existential risk because no one yet fully understands the potential of these models. Sunak also believes that before formulating (AI) related regulations, the security features and specifications of artificial intelligence should be clarified first, such as digital watermarking, information sharing, transparency of training data sets, etc., and research can be strengthened by setting up special research institutions and security assessment capabilities.

According to IT House citing a BBC report, the UK is planning to provide a new type of artificial intelligence technology to all NHS (National Health Service System) trusts at a cost price, which can help doctors calculate the placement of radiotherapy radiation beams faster, Thereby effectively reducing the time for patients to receive radiotherapy. The AI, called InnerEye, was jointly trained by Microsoft and Addenbrooke's Hospital in the UK. After training, the AI can draw the contour details of the human body with 90% accuracy, and the doctor will still check the drawing results manually. In about two-thirds of cases, doctors can use the mapping results directly for radiation therapy without any modification, which is 2.5 times faster than previous scanning and mapping. The NHS AI Lab has given £500,000 to Addenbrooke's Hospital to fund the necessary safety checks and assessments. The UK government has been investing in artificial intelligence projects in the NHS, and InnerEye is the first NHS-funded AI-assisted program in medical imaging.

According to 36 Krypton reports, on June 1, the State Drug Administration announced that Tencent Miying’s product “Colon polyp electronic endoscope image-aided detection software” was approved for listing. According to reports, this artificial intelligence-assisted detection product that has passed the review of innovative medical devices can help improve the detection rate of polyps and assist clinicians in more efficient and accurate detection of colon polyps, thereby reducing the incidence and mortality of colon cancer.